



## **ASX APPENDIX 3Y Clarification Announcement - 13<sup>th</sup> July 2022**

Further to the ASX Appendix 3Y announcement released to the market on Monday 11 July 2022, Medlab (ASX:MDC) advises an administrative error was made.

The date of change was noted as 12 April 2022. This date should read **08 July 2022**. Secondly, the starting position in the Appendix 3Y released on 11 July 2022 did not match the final position of the Appendix 3Y released on 04 April 2022. The direct holding starting position should read **58,231,189**, and not 58,121,299 plus 205,634 shares.

In order to meet disclosure requirements under listing 3.19B, MDC has a share trading policy where directors must notify the Company Secretary immediately after any share transaction has taken place. The Company believes processes and procedures are adequate.

Please find attached revised Appendix 3Y.

Yours Sincerely

Kerem Kaya

CFO and Company Secretary

**- ENDS -**

### **Authorisation & Additional information**

This announcement was authorised by the Board of Directors of Medlab Clinical Limited.

### **About Medlab Clinical:**

Medlab Clinical LTD (ASX:MDC) is pioneering the development and Commercialisation of a delivery technology, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability.

Medlab's pipeline comprises several small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies.

NanoCelle®, the patented delivery platform is wholly owned by Medlab and developed in Medlab's owned OGTR Registered Laboratory.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Medlab Clinical Limited</b>
<b>ABN</b>	<b>51 169 149 071</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Sean Michael Hall
<b>Date of last notice</b>	04 April 2022

### **Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (Including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	a) Sean Michael Hall b) Comdox No 229 Pty Ltd
<b>Date of change</b>	8 July 2022
<b>No. of securities held prior to change</b>	a) 58,231,189 Ordinary shares 4,000,000 unlisted \$0.20 options expiring 31 October 2022 b) 500,000 Ordinary Shares
<b>Class</b>	Ordinary shares
<b>Number acquired</b>	124,821 Ordinary shares
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$9,999.93 (ex. Brokerage)

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held after change</b>	a) 58,356,010 Ordinary shares 4,000,000 unlisted \$0.20 options expiring 31 October 2022 b) 500,000 Ordinary Shares
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market trade

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (If issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

## Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	